Showing results (1741-1750 of 1,755) with videos related to

Sort By:
Pageof 176
Cancers|March 11, 2023
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry StudyJoaquín Martínez-López, Javier De la Cruz, Rodrigo Gil-Manso, et al.
Medicina Intensiva|April 24, 2022
Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective studyÁ Estella, J L Garcia Garmendia, C de la Fuente, et al.
Medicina Intensiva|April 4, 2021
Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective studyÁ Estella, J L Garcia Garmendia, C de la Fuente, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|January 9, 2023
Lifting COVID-19 mitigation measures in Spain (May-June 2020)Susana Monge, Pello Latasa Zamalloa, María José Sierra Moros, et al.
Nature|August 23, 2019
Conserved cell types with divergent features in human versus mouse cortexRebecca D Hodge, Trygve E Bakken, Jeremy A Miller, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|January 9, 2023
Lifting COVID-19 mitigation measures in Spain (May-June 2020)Susana Monge, Pello Latasa Zamalloa, María José Sierra Moros, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|July 18, 2021
Lifting COVID-19 mitigation measures in Spain (May-June 2020)Susana Monge, Pello Latasa Zamalloa, María José Sierra Moros, et al.
Clinical and Experimental Rheumatology|May 23, 2020
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practiceMónica Calderón-Goercke, Santos Castañeda, Vicente Aldasoro, et al.
Seminars in Arthritis and Rheumatism|January 19, 2019
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practiceMónica Calderón-Goercke, Javier Loricera, Vicente Aldasoro, et al.
Lancet (London, England)|July 9, 2026
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trialFrancesco Cogliati Dezza, Lydia Barrera Pulido, Irene Borreguero Borreguero, et al.
Pageof 176